BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder

ANAHEIM, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) ("Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has engaged IRISYS, LLC, a contract pharmaceutical product development and manufacturing services company, for the development and manufacturing of BICX102, a multi-month sustained release naltrexone implant. The Company plans to conduct clinical trials and seek FDA approval for BICX102 as a treatment for opioid and alcohol use disorders.

"We look forward to partnering with such a reputable partner as IRISYS to manufacture our naltrexone implant," said Brady Granier, CEO and President of BioCorRx, Inc. "Having received the National Institute on Drug Abuse grant award last month and following a pre-IND meeting we had with the FDA last year, we are now in a position to begin the manufacturing and development process for our lead pharmaceutical candidate, BICX102. IRISYS brings valuable experience beyond manufacturing that should also contribute to our success as we move forward through the clinical and regulatory process for BICX102."

IRISYS was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, as well as strategic consulting related to the drug development process. IRISYS' custom approach to drug development is supported by its scientific and regulatory experience in moving more than a hundred drug products from discovery to clinical development and commercialization. For more information about IRISYS, visit www.irisys.com

"IRISYS is pleased to contribute its expertise to the development of BICX102, which promises to be a significant factor in addiction recovery and we believe it will aid in the effort to combat the national opioid crisis," stated Robert Giannini, Ph.D., CSO/CTO of IRISYS.

According to the National Institute of Drug Abuse, more than 130 people in the United States die every day of an opioid overdose and the White House declared it a national Public Health Emergency on Oct. 26, 2017. The abuse and misuse of opioids has fostered a $1.4 billion opioid addiction treatment industry in the U.S., as of 2014, according to the Addiction Treatment Advisory Group's (ATAG) report.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com.

Twitter:            @BioCorRxInc

LinkedIn:          https://www.linkedin.com/company/biocorrx-inc/

Facebook:       @BioCorRx

Instagram:       @biocorrx_inc

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

To read more Press Release articles, click here.